Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type 2 Diabetes Mellitus

References

• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695. doi:10.1056/NEJMra043430
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–519. doi:10.1038/nri1882
   PubMed Web of Science ®Google Scholar
• Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–533. doi:10.1038/s41586-021-03392-8
   PubMed Web of Science ®Google Scholar
• Baeyens N, Bandyopadhyay C, Coon BG, Yun S, Schwartz MA. Endothelial fluid shear stress sensing in vascular health and disease. J Clin Invest. 2016;126(3):821–828. doi:10.1172/JCI83083
   PubMed Web of Science ®Google Scholar
• Barbu E, Popescu MR, Popescu AC, Balanescu SM. Inflammation as a precursor of atherothrombosis, diabetes and early vascular aging. Int J Mol Sci. 2022;23(2):963. doi:10.3390/ijms23020963
   PubMed Web of Science ®Google Scholar
• Kaneko S. Novel approaches to pharmacological management of type 2 diabetes in Japan. Expert Opin Pharmacother. 2021;22(16):2235–2249. doi:10.1080/14656566.2021.1974401
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531. doi:10.1210/er.2010-0029
   PubMed Web of Science ®Google Scholar
• Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium–glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? J Hypertens. 2015;33(11):2185–2197. doi:10.1097/HJH.0000000000000719
   PubMed Web of Science ®Google Scholar
• Solini A, Giannini L, Seghieri M, et al. Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study. Cardiovasc Diabetol. 2017;16(1):138. doi:10.1186/s12933-017-0621-8
   PubMed Web of Science ®Google Scholar
• Lim S, Eckel RH, Koh KK. Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. Atherosclerosis. 2018;272:33–40. doi:10.1016/j.atherosclerosis.2018.03
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, Chiodini P, Esposito K. Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. J Am Heart Assoc. 2019;8(12):e012356. doi:10.1161/JAHA.119.012356
   PubMed Web of Science ®Google Scholar
• Scheen AJ. SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients. Diabetes Met Obes. 2020;13:2765–2779. doi:10.2147/DMSO.S193528
   PubMed Web of Science ®Google Scholar
• Cai X, Han X, Luo Y, Ji L. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes. 2015;7(3):347–359. doi:10.1111/1753-0407.12196
   PubMed Web of Science ®Google Scholar
• Zhou Y, Geng Z, Wang X, Huang Y, Shen L, Wang Y. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes. Diabetes Metab Res Rev. 2020;36(2):e3223. doi:10.1002/dmrr.3223
   PubMed Web of Science ®Google Scholar
• Poole RM, Pressler JE. Tofogliflozin: first global approval. Drugs. 2014;74(8):939–944. doi:10.1007/s40265-014-0229-1
   PubMed Web of Science ®Google Scholar
• Kaku K, Watada H, Iwamoto Y, et al. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65. doi:10.1186/1475-2840-13-65
   PubMed Web of Science ®Google Scholar
• Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium/glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15(6):749–766. doi:10.1517/14656566.2014.887680
   PubMed Web of Science ®Google Scholar
• Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17(10):984–993. doi:10.1111/dom.12538
   PubMed Web of Science ®Google Scholar
• Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018;20(5):1176–1185. doi:10.1111/dom.13213
   PubMed Web of Science ®Google Scholar
• Iwahashi Y, Hirose S, Nakajima S, Seo A, Takahashi T, Tamori Y. Evaluation of metabolic parameters and body composition in Japanese patients with type 2 diabetes mellitus who were administered tofogliflozin for 48 weeks. Diabetol Int. 2016;8(2):205–211. doi:10.1007/s13340-016-0295-6.
   PubMedGoogle Scholar
• Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes. 2014;4(7):e125. doi:10.1038/nutd.2014.20
   PubMedGoogle Scholar
• Kamei S, Iwamoto M, Kameyama M, et al. Effect of tofogliflozin on body composition and glycemic control in Japanese subjects with type 2 diabetes mellitus. J Diabetes Res. 2018;2018:6470137. doi:10.1155/2018/6470137
   PubMed Web of Science ®Google Scholar
• Kitazawa T, Seino H, Ohashi H, et al. Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: a randomized, 24-week, open-label, controlled trial (STOP-OB). Diabetes Obes Metab. 2020;22(9):1659–1663. doi:10.1111/dom.14059
   PubMed Web of Science ®Google Scholar
• Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362–376. doi:10.1007/s00535-017-1415-1
   PubMed Web of Science ®Google Scholar
• Matsuba R, Matsuba I, Shimokawa M, Nagai Y, Tanaka Y. Tofogliflozin decreases body fat mass and improves peripheral insulin resistance. Diabetes Obes Metab. 2018;20(5):1311–1315. doi:10.1111/dom.13211
   PubMed Web of Science ®Google Scholar
• Takeshita Y, Honda M, Harada K, et al. Comparison of tofogliflozin and glimepiride effects on nonalcoholic fatty liver disease in participants with type 2 diabetes: a randomized, 48-week, open-label, active-controlled trial. Diabetes Care. 2022;45(9):2064–2075. doi:10.2337/dc21-2049
   PubMed Web of Science ®Google Scholar
• Yoneda M, Kobayashi T, Honda Y, et al. Combination of tofogliflozin and pioglitazone for NAFLD: extension to the ToPiND randomized controlled trial. Hepatol Commun. 2022;6(9):2273–2785. doi:10.1002/hep4.1993
   PubMed Web of Science ®Google Scholar
• Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132(12):1329–1339. doi:10.1042/CS20171298
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Beeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021;17(5):319–334. doi:10.1038/s41581-021-00393-8
   PubMed Web of Science ®Google Scholar
• Nunoi K, Sato Y, Kaku K, Yoshida A, Suganami H. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes. Endocrinol Diabetes Metab. 2018;1(2):e00015. doi:10.1002/edm2.15
   PubMedGoogle Scholar
• Li Z, Murakoshi M, Ichikawa S, et al. The sodium-glucose cotransporter inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice. FEBS Open Bio. 2020;10(12):2761–2770. doi:10.1002/2211-5463.13014
   PubMed Web of Science ®Google Scholar
• Miyazaki Y, Nomura S, Miyake T, et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 1996;88(9):3456–3464. doi:10.1182/blood.V88.9.3456.bloodjournal8893456
   PubMed Web of Science ®Google Scholar
• Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res. 2008;123(1):8–23. doi:10.1016/j.thromres
   PubMed Web of Science ®Google Scholar
• Nomura S, Shouzu A, Taomoto K, et al. Assessment of an ELISA kit for platelet-derived microparticles by joint research at many institutes in Japan. J Atheroscler Thromb. 2009;16(6):878–887. doi:10.5551/jat.2642.
   PubMed Web of Science ®Google Scholar
• Nomura S. Microparticle and atherothrombotic diseases. J Atheroscler Thromb. 2016;23(1):1–9. doi:10.5551/jat.32326
   PubMed Web of Science ®Google Scholar
• Nomura S. Extracellular vesicles and blood diseases. Int J Hematol. 2017;105(4):392–405. doi:10.1007/s12185-017-2180-x
   PubMed Web of Science ®Google Scholar
• Nomura S, Tandon NN, Nakamura T, Cone J, Fukuhara S, Kambayashi J. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis. 2001;158(2):277–287. doi:10.1016/s00219150(01)004336
   PubMed Web of Science ®Google Scholar
• Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler Thromb Vasc Biol. 2004;24(1):29–33. doi:10.1161/01.ATV.0000099786.99623.EF.
   PubMed Web of Science ®Google Scholar
• Takahara M, Katakami N, Kaneto H, Noguchi M, Shimomura I. Contribution of visceral fat accumulation and adiponectin to the clustering of metabolic abnormalities in a Japanese population. J Atheroscler Thromb. 2014;21(6):543–553.
   PubMed Web of Science ®Google Scholar
• Ouchi N. Adipocytokines in cardiovascular and metabolic diseases. J Atheroscler Thromb. 2016;23(6):645–654. doi:10.5551/jat.34918
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Kubota T, Sakurai Y, et al. The sodium-glucose co-transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE-deficient mice with streptozotocin-induced diabetes. Pharmacol Res Perspect. 2022;10(4):e00971. doi:10.1002/prp2.971
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Yoshii H, et al. The influence of tofogliflozin on treatment-related quality of life in patients with type 2 diabetes mellitus. Diabetes Ther. 2021;12(9):2499–2515. doi:10.1007/s13300-021-01125-8
   PubMed Web of Science ®Google Scholar
• Katakami N, Mita T, Maeda N, Sato Y, Watada H, Shimomura I. Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall-a sub-analysis of UTOPIA trial. Cardiovasc Diabetol. 2022;21(9):19. doi:10.1186/s12933-022-01451-6
   PubMedGoogle Scholar
• Sawamura T, Kume N, Aoyama T, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386(6620):73–77. doi:10.1038/386073a0
   PubMed Web of Science ®Google Scholar
• Yokota C, Sawamura T, Watanabe M, et al. High levels of soluble lectin-like oxidized low-density lipoprotein receptor-1 in acute stroke: an age- and sex-matched cross-sectional study. J Atheroscler Thromb. 2016;23(10):1222–1226. doi:10.5551/jat.32466
   PubMed Web of Science ®Google Scholar
• Sawamura T, Fujita Y, Horiuchi S, Kakino A. LOX-1 in ischemic stroke. J Atheroscler Thromb. 2017;24(6):566–568. doi:10.5551/jat.ED071.2009
   PubMed Web of Science ®Google Scholar
• Fukui M, Tanaka M, Senmaru T, et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism. 2013;62(7):935–938. doi:10.1016/j.metabol.2013.01.018
   PubMed Web of Science ®Google Scholar
• Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked? J Cell Biochem. 2017;118(11):3577–3585. doi:10.1002/jcb.26097
   PubMed Web of Science ®Google Scholar
• Yuan T, Yang T, Chen H, et al. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247–260. doi:10.1016/j.redox.2018.09.025
   PubMed Web of Science ®Google Scholar
• Yu XH, Fu YC, Zhang DW, Yin K, Tang CK. Foam cells in atherosclerosis. Clin Chim Acta. 2013;424:245–252. doi:10.1016/j.cca.2013.06.006
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Yamagishi S. Tofogliflozin, a highly selective inhibitor of SGLT2 blocks proinflammatory and proapoptotic effects of glucose overload on proximal tubular cells partly by suppressing oxidative stress generation. Horm Metab Res. 2016;48(3):191–195. doi:10.1055/s-0035-1555791
   PubMed Web of Science ®Google Scholar